7 results
Summary of characteristics of Platelet Aggregation Inhibitors

#AntiPlatelet #Inhibitors #Pharmacology #Table #Overview #Interactions #Pharmacology #Cardiology
Summary of characteristics ... #AntiPlatelet #Inhibitors ... #Pharmacology # ... Table #Overview ... #Cardiology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... Summary Mechanisms ... #Pharmacology # ... Summary #DM2 #diabetes
NSAID Dosing in CKD
 • Carboxylic Acids: Salsalate, Choline Mg trisalicylate
 • Acetic Acids: Indomethacin, Tolmetin,
NSAID Dosing in ... trisalicylate • Acetic ... Nabumetone • COX-2 Inhibitors ... #CKD #pharmacology ... #table
Perioperative Management of DOACs
Problem:
 ✖ Each year approximately 250,000 patients on chronic anticoagulation in North America
anticoagulation in North America ... clearance (calculated using ... per treatment table ... direct thrombin inhibitor ... Management #Treatment #pharmacology
Clinically Significant Cardiovascular Drug-Drug Interactions With OTC Supplements and Herbal Products
Angiotensin-Converting Enzyme Inhibitors (ACEIs)
 • Night-blooming
Angiotensin-Converting Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Bilberry, Danshen, Dong ... supplementals #herbal #pharmacology ... #DDI #table #cardiology
Allopurinol Pharmacology Summary

Xanthine oxidase inhibitor blocking the formation of new uric acid
Initiate 1-2 days prior to
Allopurinol Pharmacology ... Summary Xanthine ... oxidase inhibitor ... chemotherapy Dosing ... : 100 mg/m2/dose
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
, 350 mg/m2, and ... system (RAAS) inhibitor ... every 3 months during ... Cardiotoxicity #cardiology ... #oncology #pharmacology